Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0005 USD | +150.00% | +150.00% | +25.00% |
2023 | Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023 | CI |
2023 | Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022 | CI |
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Biomedical
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +45.38% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +45.38% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Denis Corin
CEO | Chief Executive Officer | 51 | 15-04-20 |
Ari Jatwes
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 55 | 15-05-31 | |
Keith Pinder
IRC | Investor Relations Contact | - | - |
Robert Derham
PRN | Corporate Officer/Principal | - | - |
Geoff Fatzinger
LAW | General Counsel | - | 20-03-30 |
Corporate Officer/Principal | 69 | 15-12-15 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | 15-05-31 | |
Denis Corin
CEO | Chief Executive Officer | 51 | 15-04-20 |
Rick Panicucci
BRD | Director/Board Member | 63 | 18-02-12 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,000,000 | 0 | 0 | 97.01 % |
Stock B | 0 | 296,000 | 0 | 0 | |
Stock C | 0 | 500,000 | 0 | 272,002 ( 54.40 %) | |
Stock D | 1 | 145,094,531 | 140,760,821 ( 97.01 %) | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+25.00% | 72.55K | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- QBIO Stock
- Company Q BioMed Inc.